Drugs / MLC601
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01696123 | Jan 2011 → Jan 2012 | Alzheimer disease | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01336153 | Aug 2009 → Jan 2010 | stroke disorder | Shahid Beheshti University | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-08 | Moleac Pte Ltd. | Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study moleac.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MLC601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01696123 ↗ |
| Known as | NeuroAideTM | “MLC601 (NeuroAideTM) as a Traditional Chinese Medicine” NCT01336153 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “MLC601 (NeuroAideTM) as a Traditional Chinese Medicine” NCT01336153 ↗ |